Table 2.
Genetic characteristics of ovarian and endometrial cancers. The frequencies of the commonly mutated genes in ovarian and endometrial cancers are listed.
| Tissue | Type | Subtype | Somatically mutated genes (frequency) | Reference |
|---|---|---|---|---|
| Ovarian | Epithelial | High-grade serous | TP53 (96%) | (29) |
| CSMD3 (6%) | (29) | |||
| FAT3 (6%) | (29) | |||
| BRCA1 (3%) | (29) | |||
| BRCA2 (3%) | (29) | |||
| Endometrioid | TP53 (68%) | (32) | ||
| ARID1A (30%) | (32) | |||
| CTNNB1 (26%) | (32) | |||
| PTEN (17%) | (32) | |||
| PIK3CA (15%) | (32) | |||
| KRAS (10%) | (32) | |||
| PPP2R1A (11%) | (32) | |||
| CDKN2A (12%) | (32) | |||
| BRAF (8%) | (32) | |||
| Clear cell | ARID1A (57%) | (30) | ||
| PIK3CA (40%) | (30) | |||
| PPP2R1A (7%) | (30) | |||
| KRAS (4.7%) | (30) | |||
| Low-grade serous | BRAF (38%) | (31) | ||
| KRAS (19%) | (31) | |||
| Mucinous | TP53 (56%) | (32) | ||
| KRAS (40%) | (32) | |||
| PPP2R1A (33%) | (32) | |||
| CDKN2A (16%) | (32) | |||
| PTEN (11%) | (32) | |||
| Endometrial | Type I: endometrioid | Endometrioid | PTEN (64%) | Current study |
| PIK3CA (59%) | Current study | |||
| ARID1A (55%) | Current study | |||
| CTNNB1 (32%) | Current study | |||
| MLL2 (32%) | Current study | |||
| FBXW7 (27%) | Current study | |||
| RNF43 (27%) | Current study | |||
| APC (23%) | Current study | |||
| FGFR2 (18%) | Current study | |||
| KRAS (9%) | Current study | |||
| PIK3R1 (9%) | Current study | |||
| EGFR (14%) | Current study | |||
| AKT1 (5%) | Current study | |||
| NRAS (5%) | Current study | |||
| TP53 (5%) | Current study | |||
| Type II: non-endometrioid | Papillary serous | TP53 (82%) | (35) | |
| PIK3CA (24%) | (35) | |||
| FBXW7 (20%) | (35) | |||
| PPP2R1A (18%) | (35) | |||
| Clear cell | TP53 (45%) | (32) | ||
| PPP2R1A (33%) | (32) | |||
| PIK3CA (29%) | (32) | |||
| PTEN (13%) | (32) | |||
| PIK3R1 (9%) | (32) | |||
| KRAS (5%) | (32) |